Pliant Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 8, 2022 and accepted by EDGAR at Aug 8, 2022, 16:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $5.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $6.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2022-04-01 to 2022-06-30 | $26.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $47.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$29.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$57.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$29.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$57.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.82 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$1.59 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.82 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$1.59 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 36,173,135 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 36,144,944 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$44.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $898.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-06-30 | $25.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $173.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $184.6m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $22.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $36.8m | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $9.9m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-06-30 | $147.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001746473-22-000027. Last ingested by Listed: Nov 13, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.